Eligibility Criteria for objective #1: - Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules. - Patients who are undergoing a planned PET-CT scan at main campus of MSK. - Patients must be ≥ 18 years old Eligibility Criteria for objective #2: - Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously. - Patients with metastatic prostate or head and neck cancer. - Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK. - Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK - Patients must be ≥ 18 years old Eligibility Criteria for objective #3: - Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer). - Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an [18F]-fluormisonidazole PET-CT scan at the main campus of MSK. - Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection) - Patients must be ≥ 18 years old

• Patients who suffer from claustrophobia. - Women who are pregnant or breast-feeding. - Patients < 18 years of age